Drugs That Distort ANA Test Results

What the ANA Test Measures and Why It Matters

The antinuclear antibody test detects autoantibodies directed against components of the cell nucleus, including DNA, histones, and ribonucleoproteins. Clinicians order ANA testing as a first-line screen when symptoms suggest systemic lupus erythematosus (SLE), Sjögren syndrome, scleroderma, or mixed connective tissue disease. A positive result prompts reflex testing for specific antibodies (anti-dsDNA, anti-Smith, anti-SSA/SSB) to narrow the diagnosis.

The American College of Rheumatology (ACR) recommends indirect immunofluorescence (IIF) on HEp-2 cells as the gold-standard screening method [1]. Results are reported as a titer (1:40, 1:80, 1:160, and so on) along with a staining pattern (homogeneous, speckled, nucleolar, centromere). A titer of 1:80 or higher is generally considered clinically significant, though context determines interpretation. Roughly 25-30% of healthy individuals test positive at 1:40, and about 5% test positive at 1:80, according to a large population-based study published in Arthritis & Rheumatism [2]. Age and sex shift the baseline: healthy women over 65 carry ANA-positivity rates approaching 20% at 1:80.

The problem arises when a medication, not the immune system, drives the positive result. A 2012 review in Lupus cataloged over 100 drugs associated with ANA seroconversion or overt drug-induced lupus (DIL) [3]. Because ANA screening is so common, clinicians encounter drug-related false positives frequently, and misinterpreting them wastes time, money, and patient trust.

How Drugs Cause False-Positive ANA Results

Drug-induced ANA positivity follows two broad mechanisms. The first is direct immunomodulation. Certain drugs alter DNA methylation in T lymphocytes, reactivating silenced genes and producing autoreactive T cells that drive B-cell production of antinuclear antibodies. Hydralazine and procainamide are classic examples; both inhibit DNA methyltransferase activity, and this epigenetic disruption is well documented in studies published in the Journal of Clinical Investigation [4].

The second mechanism involves hapten formation. A drug or its metabolite binds to nuclear proteins, creating a neoantigen the immune system recognizes as foreign. The resulting antibody response registers as a positive ANA on standard assays.

Not every drug-induced ANA converts to clinical lupus. Procainamide causes ANA seroconversion in 50-90% of patients within 12 months of use, yet only 15-20% develop symptomatic drug-induced lupus [5]. The gap between serologic positivity and clinical disease is wide, and this distinction is the single most important concept for patients on these medications.

Anti-histone antibodies serve as a useful discriminator. They are present in 75-95% of drug-induced lupus cases, compared with about 50-70% in idiopathic SLE [6]. When a patient on a known offending drug tests ANA-positive, checking anti-histone antibodies helps separate drug effect from coincidental autoimmune disease.

The Major Drug Offenders: A Category-by-Category Breakdown

Cardiovascular Drugs

Hydralazine tops the list. It is the drug most frequently associated with full-blown drug-induced lupus, not just ANA positivity. Risk correlates with dose, duration, and acetylator status. Slow acetylators (roughly 50% of White and Black Americans) accumulate the parent compound longer, increasing exposure of nuclear antigens to the immune system. A cumulative dose exceeding 200 g raises the risk substantially. Symptomatic lupus develops in 5-8% of hydralazine users, while ANA seroconversion occurs in up to 30% [7].

Procainamide carries the highest rate of ANA seroconversion among all drugs. Up to 90% of patients become ANA-positive within a year. Symptomatic drug-induced lupus develops in 15-20% of those [5]. The widespread shift away from procainamide for arrhythmia management has reduced the clinical burden, but the drug remains a textbook reference point.

Methyldopa, quinidine, and certain beta-blockers (acebutolol in particular) are also documented triggers, though with lower frequency than hydralazine or procainamide [3].

Anti-Infective Agents

Isoniazid, the cornerstone of tuberculosis treatment, induces ANA positivity in approximately 20-25% of treated patients [8]. Drug-induced lupus is less common, developing in roughly 1% of users, but given the millions of people on isoniazid globally, the absolute case count is significant.

Minocycline, a tetracycline-class antibiotic widely used for acne, is a well-recognized cause of drug-induced autoimmunity in younger patients. A case series in the British Journal of Dermatology found that minocycline-induced autoimmunity typically manifests after months to years of daily use, with arthralgia and positive ANA as the most common features [9]. Because minocycline is prescribed to adolescents and young adults who rarely expect autoimmune testing, these cases can be diagnostically confusing.

Nitrofurantoin, prescribed for recurrent urinary tract infections, has been associated with both ANA seroconversion and a lupus-like hepatitis syndrome in postmarketing surveillance [3].

Biologic and Targeted Therapies

TNF-alpha inhibitors represent the most clinically relevant modern category. Infliximab, etanercept, and adalimumab all induce ANA positivity at notable rates. In a study from the Annals of the Rheumatic Diseases, up to 50% of patients on infliximab developed new ANA positivity during the first year of therapy [10]. Anti-dsDNA antibodies appeared in 15-20% of treated patients. Full drug-induced lupus occurred in fewer than 1% of cases, but given the large population on TNF inhibitors, clinicians encounter it regularly.

This creates a clinical paradox: a patient started on a TNF inhibitor for rheumatoid arthritis may develop new ANA positivity, raising the question of whether underlying lupus is emerging or whether the biologic itself is responsible. The decision framework most rheumatologists apply is straightforward. If the patient has no new lupus-specific symptoms (serositis, malar rash, nephritis, cytopenias) and anti-histone antibodies are positive with negative anti-dsDNA, the biologic is the likely cause and can often be continued with monitoring.

Interferon-alpha therapy, used in hepatitis C treatment and certain malignancies, is another potent inducer. ANA positivity develops in 15-35% of patients on interferon-alpha regimens, with clinical autoimmune disease in 5-10% [11].

Checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab) are increasingly recognized as triggers for autoantibody production, including ANA, though their primary immune-related adverse events tend to manifest as organ-specific conditions (thyroiditis, hepatitis, colitis) rather than classic lupus.

Psychiatric and Neurologic Drugs

Phenytoin, carbamazepine, and valproic acid have all been associated with ANA positivity and, rarely, a lupus-like syndrome [3]. Chlorpromazine was historically one of the most commonly implicated psychiatric drugs, with ANA seroconversion rates of 20-50% in long-term users. Modern antipsychotic prescribing has shifted away from chlorpromazine, but the mechanism (altered apoptotic cell clearance leading to neoantigen exposure) remains relevant.

Lithium has occasional case reports linking it to ANA positivity, though the evidence base is thin compared to the drugs above.

Other Notable Agents

Sulfasalazine, used in inflammatory bowel disease and rheumatoid arthritis, can induce ANA positivity in 5-10% of patients. D-penicillamine, once used for Wilson disease and rheumatoid arthritis, carries a well-documented risk. Statins have been reported in isolated cases, though the clinical significance appears low [3].

Drug-Induced Lupus vs. Idiopathic SLE: Key Differences

Drug-induced lupus mimics SLE but has a distinct profile. The 2012 review in Lupus identified several distinguishing features [3]. DIL presents predominantly with arthralgia, myalgia, serositis, and constitutional symptoms. Renal and central nervous system involvement is rare in DIL, affecting fewer than 5% of cases, compared with 40-60% in SLE.

Demographically, DIL mirrors the population taking the offending drug. Because hydralazine and procainamide are prescribed more often to older adults, DIL has an older average age of onset and a more equal sex distribution than SLE, which overwhelmingly affects women of reproductive age.

Lab findings also diverge. Complement levels (C3, C4) are typically normal in DIL and often depressed in active SLE. Anti-dsDNA antibodies are rare in DIL (except TNF-inhibitor-associated cases) but present in 60-70% of SLE patients [6]. Anti-histone antibodies, as noted, are the serologic hallmark of DIL.

Recovery after drug discontinuation is the strongest differentiator. Symptoms of DIL generally resolve within days to weeks after stopping the offending agent. ANA titers decline over 3-12 months and may eventually become negative [5]. In SLE, disease persists regardless of medication changes.

Clinical Approach: When a Patient on Medication Tests ANA-Positive

The practical question facing the ordering clinician is whether a positive ANA on a medicated patient reflects real autoimmune disease or drug interference. A systematic approach reduces unnecessary referrals and repeat testing.

Step one: check the medication list against known offenders. If the patient takes hydralazine, procainamide, isoniazid, minocycline, a TNF inhibitor, or another high-risk drug, drug-induced ANA is on the differential.

Step two: evaluate the clinical picture. Joint pain, rash, fever, and serositis in a patient on a known trigger drug point toward drug-induced lupus. Isolated ANA positivity without symptoms suggests serologic conversion without clinical disease.

Step three: order anti-histone antibodies, anti-dsDNA, complement levels (C3, C4), and a complete blood count. A pattern of positive anti-histone, negative anti-dsDNA, and normal complement strongly suggests drug etiology [6].

Step four: if drug-induced lupus is suspected and the offending drug is not medically irreplaceable, discontinue or substitute it. Monitor symptom resolution and repeat ANA in 3-6 months.

The Endocrine Society and AACE guidelines do not specifically address drug-induced ANA in the context of hormone therapy, but clinicians managing patients on testosterone replacement or estrogen therapy should note that exogenous hormones can modulate immune function. Estrogen, in particular, has well-documented immunostimulatory effects, and case reports exist linking hormone replacement therapy with ANA seroconversion, though large-scale data are lacking [12].

Normal ANA Range and Interpretation Basics

ANA results are not reported in conventional units like mg/dL. They use titers determined by serial dilution. The lowest dilution at which fluorescence is still detected becomes the reported titer. A negative result at 1:40 is considered normal. Titers of 1:80 or above warrant clinical correlation.

The 2019 EULAR/ACR classification criteria for SLE require a positive ANA at titer 1:80 or greater on HEp-2 cells as an entry criterion [13]. This threshold was chosen because it provides high sensitivity (98%) for SLE while accepting moderate specificity. In other words, many ANA-positive patients do not have lupus, but almost all lupus patients have a positive ANA.

Staining patterns add diagnostic information. A homogeneous pattern is most associated with SLE and drug-induced lupus. A speckled pattern suggests Sjögren syndrome or mixed connective tissue disease. Nucleolar patterns point toward scleroderma. Centromere patterns are characteristic of limited scleroderma (CREST syndrome). The pattern does not change the titer but helps guide downstream testing.

Laboratories increasingly use multiplex immunoassays (MIA) or enzyme-linked immunosorbent assays (ELISA) instead of IIF. The ACR position statement published in Arthritis Care & Research cautions that these newer methods may miss certain ANA patterns and recommends IIF as the reference standard [1]. When a drug interaction is suspected, confirming ANA by IIF on HEp-2 cells is particularly valuable because the staining pattern itself can suggest drug etiology (homogeneous anti-histone pattern).

Can You Lower or Raise ANA Levels?

ANA is not a modifiable biomarker in the way LDL cholesterol or hemoglobin A1c can be targeted with lifestyle changes. No supplement, diet, or exercise regimen has been shown in controlled trials to reduce ANA titers. Claims circulating online about anti-inflammatory diets or turmeric "lowering ANA" lack clinical evidence.

The only reliable way to reduce a drug-induced ANA is to stop the causative medication. After discontinuation, the immune system gradually clears the autoantibodies. This process takes months. A study of procainamide-induced ANA found that titers returned to negative in a median of 6-9 months after drug cessation [5].

For patients with idiopathic SLE, immunosuppressive therapy (hydroxychloroquine, mycophenolate, belimumab) can reduce disease activity and may lower ANA titers indirectly, but ANA normalization is not a treatment target. The Lupus Foundation of America notes that ANA can remain positive even when disease is well-controlled [14].

Conversely, no clinical scenario calls for "raising" ANA levels. ANA is a diagnostic marker, not a health indicator that benefits from higher values.

Specific Populations: Who Faces the Highest Risk?

Slow acetylators face disproportionate risk from hydralazine and procainamide. Acetylator phenotype is genetically determined by NAT2 polymorphisms, and testing is available though rarely ordered in routine practice [7]. Women are more susceptible to drug-induced lupus from minocycline and hydralazine, possibly due to estrogen-mediated immune enhancement.

Patients with pre-existing autoimmune tendencies (family history of SLE, baseline low-titer ANA) may seroconvert faster on offending drugs. A prospective study in the Journal of Rheumatology found that patients who were already ANA-positive at low titer before starting TNF inhibitor therapy were more likely to develop higher titers and clinical symptoms during treatment [15].

Older adults on multiple medications present a particular challenge because polypharmacy increases the probability of exposure to at least one ANA-inducing drug. In this population, a positive ANA finding should always include a careful medication reconciliation before pursuing an autoimmune workup.